JP2013198490A5 - - Google Patents

Download PDF

Info

Publication number
JP2013198490A5
JP2013198490A5 JP2013114057A JP2013114057A JP2013198490A5 JP 2013198490 A5 JP2013198490 A5 JP 2013198490A5 JP 2013114057 A JP2013114057 A JP 2013114057A JP 2013114057 A JP2013114057 A JP 2013114057A JP 2013198490 A5 JP2013198490 A5 JP 2013198490A5
Authority
JP
Japan
Prior art keywords
mab
antigen
seq
binding fragment
group
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2013114057A
Other languages
English (en)
Japanese (ja)
Other versions
JP5756147B2 (ja
JP2013198490A (ja
Filing date
Publication date
Application filed filed Critical
Publication of JP2013198490A publication Critical patent/JP2013198490A/ja
Publication of JP2013198490A5 publication Critical patent/JP2013198490A5/ja
Application granted granted Critical
Publication of JP5756147B2 publication Critical patent/JP5756147B2/ja
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

JP2013114057A 2003-05-09 2013-05-30 Ｃｄ２０特異的抗体およびその使用方法 Expired - Fee Related JP5756147B2 (ja)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US46945103P 2003-05-09 2003-05-09
US60/469,451 2003-05-09

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
JP2010163432A Division JP2011015683A (ja) 2003-05-09 2010-07-20 Ｃｄ２０特異的抗体およびその使用方法

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2014236224A Division JP5969577B2 (ja) 2003-05-09 2014-11-21 Ｃｄ２０特異的抗体およびその使用方法

Publications (3)

Publication Number Publication Date
JP2013198490A JP2013198490A (ja) 2013-10-03
JP2013198490A5 true JP2013198490A5 (enExample) 2013-11-21
JP5756147B2 JP5756147B2 (ja) 2015-07-29

Family

ID=33551414

Family Applications (6)

Application Number Title Priority Date Filing Date
JP2006532859A Expired - Fee Related JP5416338B2 (ja) 2003-05-09 2004-05-07 Ｃｄ２０特異的抗体およびその使用方法
JP2010163432A Pending JP2011015683A (ja) 2003-05-09 2010-07-20 Ｃｄ２０特異的抗体およびその使用方法
JP2013114057A Expired - Fee Related JP5756147B2 (ja) 2003-05-09 2013-05-30 Ｃｄ２０特異的抗体およびその使用方法
JP2014236224A Expired - Fee Related JP5969577B2 (ja) 2003-05-09 2014-11-21 Ｃｄ２０特異的抗体およびその使用方法
JP2016049258A Withdrawn JP2016146840A (ja) 2003-05-09 2016-03-14 Ｃｄ２０特異的抗体およびその使用方法
JP2018023333A Pending JP2018082723A (ja) 2003-05-09 2018-02-13 Ｃｄ２０特異的抗体およびその使用方法

Family Applications Before (2)

Application Number Title Priority Date Filing Date
JP2006532859A Expired - Fee Related JP5416338B2 (ja) 2003-05-09 2004-05-07 Ｃｄ２０特異的抗体およびその使用方法
JP2010163432A Pending JP2011015683A (ja) 2003-05-09 2010-07-20 Ｃｄ２０特異的抗体およびその使用方法

Family Applications After (3)

Application Number Title Priority Date Filing Date
JP2014236224A Expired - Fee Related JP5969577B2 (ja) 2003-05-09 2014-11-21 Ｃｄ２０特異的抗体およびその使用方法
JP2016049258A Withdrawn JP2016146840A (ja) 2003-05-09 2016-03-14 Ｃｄ２０特異的抗体およびその使用方法
JP2018023333A Pending JP2018082723A (ja) 2003-05-09 2018-02-13 Ｃｄ２０特異的抗体およびその使用方法

Country Status (10)

Country Link
US (2) US9416187B2 (enExample)
EP (2) EP2960251A1 (enExample)
JP (6) JP5416338B2 (enExample)
KR (2) KR101412271B1 (enExample)
CN (1) CN1802388B (enExample)
AU (1) AU2004252067B2 (enExample)
CA (2) CA2897608C (enExample)
HK (1) HK1219487A1 (enExample)
NZ (2) NZ543960A (enExample)
WO (1) WO2005000901A2 (enExample)

Families Citing this family (119)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005110249A1 (en) 2004-05-17 2005-11-24 Imp Limited Apparatus for use in orthopaedic surgery
BRPI0510915A (pt) 2004-06-04 2007-11-13 Genentech Inc método para o tratamento da esclerose múltipla e artigo manufaturado
ES2426817T3 (es) 2004-08-04 2013-10-25 Mentrik Biotech, Llc Regiones Fc variantes
EP1841454A4 (en) * 2005-01-13 2009-07-22 Genentech Inc Methods of Treatment
EP2502649A1 (en) 2005-02-03 2012-09-26 TopoTarget UK Limited Combination therapy using HDAC inhibitors and erlotinib for treating cancer
SI1853718T1 (sl) * 2005-02-15 2016-02-29 Duke University Protitelesa anti-CD19 in uporabe v onkologiji
US8444973B2 (en) 2005-02-15 2013-05-21 Duke University Anti-CD19 antibodies and uses in B cell disorders
EP2096166A1 (en) * 2005-03-31 2009-09-02 Osaka University Method for production of antibody directed against cell membrane surface antigen epitope and assaying method
ATE517183T1 (de) * 2005-03-31 2011-08-15 Biomedics Inc Monoklonaler antikörper gegen cd20
ATE542527T1 (de) 2005-05-13 2012-02-15 Topotarget Uk Ltd Pharmazeutische formulierungen von hdac-hemmern
EP1902320B1 (en) 2005-05-20 2010-03-10 Genentech, Inc. Pretreatment of a biological sample from an autoimmune disease subject
US20070014720A1 (en) * 2005-06-02 2007-01-18 Gadi Gazit-Bornstein Antibodies directed to CD20 and uses thereof
CA2627923C (en) 2005-11-10 2016-01-12 Topotarget Uk Limited Histone deacetylase (hdac) inhibitors (pxdlol) for the treatment of cancer
MY149159A (en) 2005-11-15 2013-07-31 Hoffmann La Roche Method for treating joint damage
MX2009007632A (es) 2007-01-22 2009-07-24 Genentech Inc Precipitacion de polielectrolito y purificacion de proteinas.
EP2014681A1 (en) * 2007-07-12 2009-01-14 Pierre Fabre Medicament Novel antibodies inhibiting c-met dimerization, and uses thereof
AU2016228280B2 (en) * 2007-07-12 2019-02-21 Pierre Fabre Medicament Novel antibodies inhibiting c-met dimerization, and uses thereof
US7879984B2 (en) 2007-07-31 2011-02-01 Regeneron Pharmaceuticals, Inc. Human antibodies to human CD20 and method of using thereof
US8642809B2 (en) 2007-09-25 2014-02-04 Topotarget Uk Ltd. Methods of synthesis of certain hydroxamic acid compounds
BRPI0817182A2 (pt) 2007-10-30 2015-03-17 Genentech Inc Método para purificar um anticorpo e composições
US9669057B2 (en) 2008-04-25 2017-06-06 Duke University Regulatory B cells and their uses
US10611835B2 (en) * 2008-07-10 2020-04-07 Toray Industries, Inc. Pharmaceutical composition for treatment and prevention of cancer
US8652843B2 (en) 2008-08-12 2014-02-18 Oncomed Pharmaceuticals, Inc. DDR1-binding agents and methods of use thereof
CN102149724B (zh) 2008-08-14 2014-04-09 健泰科生物技术公司 使用原地蛋白质置换离子交换膜层析清除污染物的方法
DE102008044845B4 (de) * 2008-08-28 2015-04-09 Epcos Ag Bias-Netzwerk
CA2734275A1 (en) 2008-09-10 2010-03-18 Genentech, Inc. Compositions and methods for the prevention of oxidative degradation of proteins
TW201438738A (zh) 2008-09-16 2014-10-16 建南德克公司 治療進展型多發性硬化症之方法
WO2010075249A2 (en) 2008-12-22 2010-07-01 Genentech, Inc. A method for treating rheumatoid arthritis with b-cell antagonists
BRPI1008441A2 (pt) * 2009-02-16 2016-10-11 Biolex Therapeutics Inc anticorpo humanizado, composição farmacêutica, método para tratar e prevenir um distúrbio de célula b em sujeito, composição de anticorpo anti-cd-20 humanizado, ácido nucléico isolado e célula hospedeira.
US8030026B2 (en) 2009-02-24 2011-10-04 Abbott Laboratories Antibodies to troponin I and methods of use thereof
JP2011097869A (ja) * 2009-11-05 2011-05-19 Japan Science & Technology Agency 抗ヒトアデノシンＡ２ａ受容体モノクローナル抗体
US9023997B2 (en) 2010-01-20 2015-05-05 Merck Sharp & Dohme Corp. Anti-ILT5 antibodies and ILT5-binding antibody fragments
WO2011091181A1 (en) 2010-01-20 2011-07-28 Tolerx, Inc. Immunoregulation by anti-ilt5 antibodies and ilt5-binding antibody fragments
WO2011100403A1 (en) 2010-02-10 2011-08-18 Immunogen, Inc Cd20 antibodies and uses thereof
TWI672318B (zh) 2010-02-24 2019-09-21 美商免疫遺傳股份有限公司 葉酸受體１抗體類和免疫共軛物類及彼等之用途
SMT201900549T1 (it) 2010-03-12 2019-11-13 Debiopharm Int Sa Molecole leganti il cd37 e loro immunoconiugati
CN106983862A (zh) 2010-03-22 2017-07-28 弗·哈夫曼-拉罗切有限公司 对于稳定含有蛋白质的制剂有用的组合物和方法
RU2012151500A (ru) 2010-05-03 2014-06-10 Дженентек, Инк. Композиции и способы, пригодные для снижения вязкости белковосодержащих составов
MY184736A (en) 2010-06-24 2021-04-20 Genentech Inc Compositions and methods containing alkylglycosides for stabilizing protein-containing formulations
JP2013541501A (ja) 2010-08-03 2013-11-14 エフ・ホフマン−ラ・ロシュ・アクチェンゲゼルシャフト 慢性リンパ性白血病（ｃｌｌ）のバイオマーカー
EP2600878A4 (en) * 2010-08-04 2014-06-11 Univ Duke REGULATORY B-CELLS AND ITS USES
EP2638067A2 (en) 2010-11-08 2013-09-18 Genentech, Inc. Subcutaneously administered anti-il-6 receptor antibody
US9814740B2 (en) 2010-12-21 2017-11-14 Duke University Methods and compositions combining immunotherapy with monocyte activation
SG193447A1 (en) * 2011-04-01 2013-10-30 Immunogen Inc Cd37-binding molecules and immunoconjugates thereof
CN114441757A (zh) 2011-04-01 2022-05-06 伊缪诺金公司 用于增加folr1癌症治疗的功效的方法
US20140178368A1 (en) * 2011-04-19 2014-06-26 Leslie Lynne SHARP Combinations of anti-4-1bb antibodies and adcc-inducing antibodies for the treatment of cancer
CN107827985A (zh) 2011-05-21 2018-03-23 宏观基因有限公司 能够与人和非人cd3结合的cd3结合分子
HRP20181846T1 (hr) 2011-12-22 2018-12-28 Genentech, Inc. Kromatografija membranom za ionsku izmjenu
EP2827903A4 (en) * 2012-03-23 2016-02-10 Sloan Kettering Inst Cancer POTENTIATION OF ANTIBODY-INDUCED COMPLEMENT-MEDIATED CYTOTOXICITY BY PI3K INHIBITION
ES2762105T3 (es) 2012-08-21 2020-05-22 Janssen Pharmaceutica Nv Anticuerpos para aripiprazol y uso de los mismos
CN104755928B (zh) * 2012-08-21 2017-05-10 詹森药业有限公司 奥氮平的抗体及其用途
TR201816416T4 (tr) 2012-08-21 2018-11-21 Janssen Pharmaceutica Nv Risperidona yönelik antikorlar ve bunların kullanımı.
JP6374387B2 (ja) 2012-08-21 2018-08-15 ヤンセン ファーマシューティカ エヌ．ベー． リスペリドンハプテンへの抗体及びその使用
ES2978909T3 (es) 2012-08-21 2024-09-23 Janssen Pharmaceutica Nv Anticuerpos contra haptenos de aripiprazol y uso de los mismos
WO2014031668A2 (en) 2012-08-21 2014-02-27 Ortho-Clinical Diagnostics, Inc Antibodies to quetiapine and use thereof
PT3663317T (pt) 2012-08-21 2023-01-23 Janssen Pharmaceutica Nv Anticorpos para haptenos de quetiapina e sua utilização
AU2013305965B2 (en) 2012-08-21 2017-08-24 Saladax Biomedical Inc. Antibodies to paliperidone and use thereof
CN104755093B (zh) 2012-08-21 2018-11-16 詹森药业有限公司 奥氮平半抗原的抗体及其用途
CA2882489A1 (en) 2012-08-21 2014-02-27 Ortho-Clinical Diagnostics, Inc. Antibodies to paliperidone haptens and use thereof
PL2890717T3 (pl) 2012-08-31 2020-08-10 Immunogen, Inc. Testy i zestawy diagnostyczne do wykrywania receptora folianu
US10017739B2 (en) 2012-09-06 2018-07-10 Duke University Methods of expanding and assessing B cells and using expanded B cells to treat disease
JOP20200236A1 (ar) 2012-09-21 2017-06-16 Regeneron Pharma الأجسام المضادة لمضاد cd3 وجزيئات ربط الأنتيجين ثنائية التحديد التي تربط cd3 وcd20 واستخداماتها
KR20150104117A (ko) 2012-12-18 2015-09-14 이칸 스쿨 오브 메디슨 엣 마운트 시나이 인플루엔자 바이러스 백신 및 그의 용도
MX2015012824A (es) 2013-03-14 2016-06-24 Abbott Lab Antigenos recombinantes ns3 del vhc y mutantes de los mismos para la deteccion mejorada de anticuerpos.
BR112015023239A8 (pt) 2013-03-14 2018-04-17 Abbott Lab ensaio de combinação de anticorpo-antígeno de hcv e métodos e composições para uso do mesmo
MX376492B (es) 2013-03-14 2025-03-07 Abbott Lab Anticuerpos monoclonares que se unen al dominio de unión a lípidos de la proteína de la cápside del virus de la hepatitis c (vhc)
WO2014159960A1 (en) 2013-03-14 2014-10-02 Icahn School Of Medicine At Mount Sinai Antibodies against influenza virus hemagglutinin and uses thereof
US20140314741A1 (en) * 2013-04-18 2014-10-23 Developmen Center For Biotechnology Human Antibody against Interleukin-20 and Treatment for Inflammatory Diseases
EP3708189B1 (en) * 2013-07-05 2023-11-29 University of Washington through its Center for Commercialization Soluble mic neutralizing monoclonal antibody for treating cancer
CN105814079B (zh) 2013-08-30 2021-02-09 伊缪诺金公司 用于检测叶酸受体1的抗体和测定
TWI701042B (zh) 2014-03-19 2020-08-11 美商再生元醫藥公司 用於腫瘤治療之方法及抗體組成物
CA2956072A1 (en) 2014-07-21 2016-01-28 Bloodworks Antibodies that recognize red blood cell antigens
WO2016061368A1 (en) * 2014-10-15 2016-04-21 The Children's Hospital Of Philadelphia Compositions and methods for treating b-lymphoid malignancies
AU2015350075B2 (en) 2014-11-17 2021-06-03 Regeneron Pharmaceuticals, Inc. Methods for tumor treatment using CD3xCD20 bispecific antibody
US10736956B2 (en) 2015-01-23 2020-08-11 Icahn School Of Medicine At Mount Sinai Influenza virus vaccination regimens
IL303972A (en) 2015-04-08 2023-08-01 Novartis Ag CD20 treatments, CD22 treatments and combined treatments with CD19 chimeric antigen receptor expressing cell
JP6771492B2 (ja) 2015-05-30 2020-10-21 モレキュラー テンプレーツ, インク.Molecular Templates, Inc. 脱免疫化された志賀毒素ａサブユニット足場及びそれを含む細胞標的化分子
CN108472361B (zh) 2015-06-08 2022-12-27 德彪发姆国际有限公司 抗cd37免疫缀合物及抗cd20抗体组合物
CN106349388B (zh) * 2015-07-17 2021-04-02 上海佳文英莉生物技术有限公司 一种促细胞程序性坏死抗体及其应用
CN108699144B (zh) 2015-08-28 2022-07-19 德彪发姆国际有限公司 用于检测cd37的抗体和测定
KR102700777B1 (ko) 2015-09-17 2024-08-29 이뮤노젠 아이엔씨 항-folr1 면역접합체를 포함하는 치료제 조합
CN108431040B (zh) 2015-12-17 2022-07-26 詹森药业有限公司 利培酮的抗体及其用途
AU2016370853A1 (en) 2015-12-17 2018-06-07 Saladax Biomedical Inc. Antibodies to quetiapine and use thereof
EP3448874A4 (en) 2016-04-29 2020-04-22 Voyager Therapeutics, Inc. COMPOSITIONS FOR TREATING A DISEASE
US11299751B2 (en) 2016-04-29 2022-04-12 Voyager Therapeutics, Inc. Compositions for the treatment of disease
WO2017218624A1 (en) 2016-06-15 2017-12-21 Icahn School Of Medicine At Mount Sinai Influenza virus hemagglutinin proteins and uses thereof
PL3507303T3 (pl) * 2016-09-01 2025-12-08 Tigatx, Inc. Przeciwciała CD20
US11278629B2 (en) 2016-11-02 2022-03-22 Debiopharm International, S.A. Methods for improving anti-CD37 immunoconjugate therapy
CA3046489A1 (en) 2016-12-07 2018-06-14 Progenity Inc. Gastrointestinal tract detection methods, devices and systems
WO2018112407A1 (en) 2016-12-15 2018-06-21 Duke University Antibodies and methods for depleting regulatory b10 cells and use in combination with immune checkpoint inhibitors
US20210138213A1 (en) 2017-03-30 2021-05-13 Progenity, Inc. Treatment of a disease of the gastrointestinal tract with an immune modulatory agent released using an ingestible device
WO2018187706A2 (en) * 2017-04-07 2018-10-11 Icahn School Of Medicine At Mount Sinai Anti-influenza b virus neuraminidase antibodies and uses thereof
WO2019056281A1 (en) * 2017-09-21 2019-03-28 Eucure (Beijing) Biopharma Co., Ltd ANTI-CTLA4 ANTIBODIES AND USES THEREOF
US12247060B2 (en) 2018-01-09 2025-03-11 Marengo Therapeutics, Inc. Calreticulin binding constructs and engineered T cells for the treatment of diseases
EP3674327A4 (en) * 2018-02-01 2021-05-05 Nanjing Iaso Biotherapeutics Co., Ltd. CHEMICAL ANTIGENIC RECEPTOR (CAR) BINDING TO BCMA AND ITS APPLICATIONS
KR20210014684A (ko) 2018-05-30 2021-02-09 데비오팜 인터네셔날 에스 에이 항-cd37 면역접합체 투약 용법
WO2019246317A1 (en) 2018-06-20 2019-12-26 Progenity, Inc. Treatment of a disease or condition in a tissue originating from the endoderm
WO2019246312A1 (en) 2018-06-20 2019-12-26 Progenity, Inc. Treatment of a disease of the gastrointestinal tract with an immunomodulator
EP3810634A4 (en) 2018-06-21 2022-07-27 Icahn School of Medicine at Mount Sinai Mosaic influenza virus hemagglutinin polypeptides and uses thereof
CA3105448A1 (en) 2018-07-03 2020-01-09 Elstar Therapeutics, Inc. Anti-tcr antibody molecules and uses thereof
IL280875B2 (en) 2018-08-31 2024-12-01 Regeneron Pharma Dosing strategy that mitigates cytokine release syndrome for cd3/c20 bispecific antibodies
CN116726361A (zh) 2018-11-19 2023-09-12 比奥拉治疗股份有限公司 用生物治疗剂治疗疾病的方法和装置
CN109593134B (zh) * 2018-12-29 2021-07-09 博生吉医药科技(苏州)有限公司 抗cd20的人源化单克隆抗体及其制剂
AU2020216494A1 (en) 2019-02-01 2021-08-12 Board Of Regents, The University Of Texas System Monoclonal antibodies against MHC-bound human Dickkopf-1 peptides and uses thereof
GB2597851B (en) 2019-02-21 2024-05-29 Marengo Therapeutics Inc Antibody molecules that bind to NKP30 and uses thereof
EP3927744A1 (en) 2019-02-21 2021-12-29 Marengo Therapeutics, Inc. Multifunctional molecules that bind to t cell related cancer cells and uses thereof
AR118536A1 (es) 2019-04-01 2021-10-20 Genentech Inc Composiciones y métodos para estabilizar formulaciones que contienen proteína
EP3959216A4 (en) 2019-04-24 2023-01-11 Icahn School of Medicine at Mount Sinai ANTI-INFLUENZA B VIRUS NEURAMINIDASE ANTIBODIES AND USES THEREOF
WO2021119482A1 (en) 2019-12-13 2021-06-17 Progenity, Inc. Ingestible device for delivery of therapeutic agent to the gastrointestinal tract
EP4084823A4 (en) 2020-01-03 2024-05-15 Marengo Therapeutics, Inc. ANTI-TCR ANTIBODY MOLECULES AND THEIR USES
JP2023516724A (ja) * 2020-03-06 2023-04-20 オーエヌエー セラピューティクス エセ．エレ． 抗ｃｄ３６抗体及び癌を治療するためのそれらの使用
CN117106084B (zh) * 2021-12-02 2024-03-22 北京东方百泰生物科技股份有限公司 一种抗tslp的单克隆抗体、其抗原结合片段及其应用
WO2023114701A2 (en) * 2021-12-13 2023-06-22 BioLegend, Inc. Cd28 binding antibodies and antigen binding fragments thereof
CN114292334B (zh) * 2021-12-24 2023-11-17 杭州贤至生物科技有限公司 抗可替宁特异性抗体、质粒载体及方法
WO2023141297A2 (en) * 2022-01-21 2023-07-27 Marengo Therapeutics, Inc. Multifunctional molecules comprising g6b binder and/or cd34 binder and uses thereof
WO2024022495A1 (en) * 2022-07-28 2024-02-01 Concept To Medicine Biotech Co., Ltd. Anti-MerTK ANTIBODIES AND USES THEREOF
EP4562054A1 (en) * 2022-07-28 2025-06-04 Icahn School of Medicine at Mount Sinai Anti-cd16a antibodies and methods of use thereof
CN118271437B (zh) * 2024-05-31 2024-08-13 江西赛基生物技术有限公司 一种抗Tau蛋白单克隆抗体及其制备方法和应用
CN119431525B (zh) * 2024-10-08 2025-04-11 北京溯本源和生物科技有限公司 狂犬病毒g蛋白重组抗原、单克隆抗体及其制备方法和应用

Family Cites Families (89)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4235871A (en) 1978-02-24 1980-11-25 Papahadjopoulos Demetrios P Method of encapsulating biologically active materials in lipid vesicles
US4554101A (en) 1981-01-09 1985-11-19 New York Blood Center, Inc. Identification and preparation of epitopes on antigens and allergens on the basis of hydrophilicity
US4501728A (en) 1983-01-06 1985-02-26 Technology Unlimited, Inc. Masking of liposomes from RES recognition
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US5019369A (en) 1984-10-22 1991-05-28 Vestar, Inc. Method of targeting tumors in humans
US5618920A (en) * 1985-11-01 1997-04-08 Xoma Corporation Modular assembly of antibody genes, antibodies prepared thereby and use
US5260203A (en) 1986-09-02 1993-11-09 Enzon, Inc. Single polypeptide chain binding molecules
US6893625B1 (en) 1986-10-27 2005-05-17 Royalty Pharma Finance Trust Chimeric antibody with specificity to human B cell surface antigen
US4837028A (en) 1986-12-24 1989-06-06 Liposome Technology, Inc. Liposomes with enhanced circulation time
IL85035A0 (en) 1987-01-08 1988-06-30 Int Genetic Eng Polynucleotide molecule,a chimeric antibody with specificity for human b cell surface antigen,a process for the preparation and methods utilizing the same
US4975278A (en) 1988-02-26 1990-12-04 Bristol-Myers Company Antibody-enzyme conjugates in combination with prodrugs for the delivery of cytotoxic agents to tumor cells
GB8720833D0 (en) 1987-09-04 1987-10-14 Celltech Ltd Recombinant dna product
US5824656A (en) 1988-01-15 1998-10-20 Merck & Co., Inc. Recombinant and native group B eimeria tenella immunogens useful as coccidiosis vaccines
US5506126A (en) 1988-02-25 1996-04-09 The General Hospital Corporation Rapid immunoselection cloning method
DE3920358A1 (de) 1989-06-22 1991-01-17 Behringwerke Ag Bispezifische und oligospezifische, mono- und oligovalente antikoerperkonstrukte, ihre herstellung und verwendung
US6713610B1 (en) 1990-01-12 2004-03-30 Raju Kucherlapati Human antibodies derived from immunized xenomice
MX9204374A (es) 1991-07-25 1993-03-01 Idec Pharma Corp Anticuerpo recombinante y metodo para su produccion.
JPH07501451A (ja) 1991-11-25 1995-02-16 エンゾン・インコーポレイテッド 多価抗原結合タンパク質
US5736137A (en) 1992-11-13 1998-04-07 Idec Pharmaceuticals Corporation Therapeutic application of chimeric and radiolabeled antibodies to human B lymphocyte restricted differentiation antigen for treatment of B cell lymphoma
DE669986T1 (de) 1992-11-13 1996-10-10 Idec Pharma Corp Völlig unfunktionelle konsensus-kozak-sequenzen zur säugetier-exprimierung.
EP1005870B1 (en) 1992-11-13 2009-01-21 Biogen Idec Inc. Therapeutic application of chimeric antibodies to human B lymphocyte restricted differentiation antigen for treatment of B cell lymphoma
US5484892A (en) 1993-05-21 1996-01-16 Dana-Farber Cancer Institute, Inc. Monoclonal antibodies that block ligand binding to the CD22 receptor in mature B cells
JP3504963B2 (ja) 1993-10-22 2004-03-08 智靖 羅 抗ヒト高親和性ＩｇＥ受容体モノクローナル抗体に係るアミノ酸配列をコードするＤＮＡ断片
US5932449A (en) 1996-02-01 1999-08-03 The United States Of America As Represented By The Secretary Of The Army Detection of botulinum toxin
JP2000516594A (ja) 1996-07-26 2000-12-12 スミスクライン・ビーチャム・コーポレイション 免疫細胞介在全身性疾患の改良された治療法
DE69739673D1 (de) 1996-11-27 2009-12-31 Genentech Inc Affinitätsreinigung von Polypeptid-Proteinen auf einer Protein A Matrix
PL191251B1 (pl) 1997-03-14 2006-04-28 Idec Pharma Corp Sposób wprowadzania żądanego DNA w docelowe miejsce w genomie ssaka i układ wektorów
US6306393B1 (en) 1997-03-24 2001-10-23 Immunomedics, Inc. Immunotherapy of B-cell malignancies using anti-CD22 antibodies
US6171586B1 (en) 1997-06-13 2001-01-09 Genentech, Inc. Antibody formulation
DK0999853T3 (da) 1997-06-13 2003-04-22 Genentech Inc Stabiliseret antostofformulering
US20040191256A1 (en) 1997-06-24 2004-09-30 Genentech, Inc. Methods and compositions for galactosylated glycoproteins
ES2244066T3 (es) 1997-06-24 2005-12-01 Genentech, Inc. Procedimiento y composiciones de glicoproteinas galactosiladas.
US20040136986A1 (en) 1997-10-31 2004-07-15 Genentech, Inc. Methods and compositions comprising glycoprotein glycoforms
EP1028751B1 (en) 1997-10-31 2008-12-31 Genentech, Inc. Methods and compositions comprising glycoprotein glycoforms
US6528624B1 (en) 1998-04-02 2003-03-04 Genentech, Inc. Polypeptide variants
US6194551B1 (en) 1998-04-02 2001-02-27 Genentech, Inc. Polypeptide variants
ES2434961T5 (es) 1998-04-20 2018-01-18 Roche Glycart Ag Ingeniería de glicosilación de anticuerpos para mejorar la citotoxicidad celular dependiente del anticuerpo
ES2228052T3 (es) 1998-06-01 2005-04-01 Genentech, Inc. Separacion demonomeros de anticuerpos de sus multimeros utilizando cromatografia de intercambio de iones.
KR101023367B1 (ko) 1998-08-11 2011-03-18 바이오겐 아이덱 인크. Ｂ-세포 림프종을 치료하기 위한 항-ｃｄ２０ 항체를 포함하는 약제
WO2000023573A2 (en) * 1998-10-20 2000-04-27 City Of Hope Cd20-specific redirected t cells and their use in cellular immunotherapy of cd20+ malignancies
BR9915149A (pt) 1998-11-09 2001-08-07 Idec Pharma Corp Tratamento com anticorpo anti-cd20 quimérico de pacientes recebendo transplantes de bmt ou de pbsc
KR20010103655A (ko) 1998-11-09 2001-11-23 케네쓰 제이. 울코트 키메라 항-ｃｄ２０항체를 이용한 순환성 종양세포와관련된 혈액학적 악성종양의 치료법
US6737056B1 (en) 1999-01-15 2004-05-18 Genentech, Inc. Polypeptide variants with altered effector function
US6897044B1 (en) 1999-01-28 2005-05-24 Biogen Idec, Inc. Production of tetravalent antibodies
US6300143B1 (en) * 1999-03-01 2001-10-09 Idec Pharmaceuticals Corporation Electrochemiluminescent assays for eukaryotic cells
HK1043312B (en) 1999-05-07 2006-07-28 Genentech, Inc. Treatment of autoimmune diseases with antagonists which bind to b cell surface markers
EP1194167B1 (en) 1999-06-09 2009-08-19 Immunomedics, Inc. Immunotherapy of autoimmune disorders using antibodies which target b-cells
ITMI991299A1 (it) 1999-06-11 2000-12-11 Consiglio Nazionale Ricerche Uso di anticorpi contro antigeni di superficie per il trattamento della malattia trapianto contro ospite
HUP0202238A3 (en) 1999-07-12 2004-05-28 Idec Pharmaceuticals Inc San D Blocking immune response to a foreign antigen using an antagonist which binds to cd20
CN101259270A (zh) 1999-08-11 2008-09-10 拜奥根Idec公司 用抗cd20抗体治疗累及骨髓的非霍奇金淋巴瘤患者
US6451284B1 (en) 1999-08-11 2002-09-17 Idec Pharmaceuticals Corporation Clinical parameters for determining hematologic toxicity prior to radioimmunotheraphy
US8557244B1 (en) 1999-08-11 2013-10-15 Biogen Idec Inc. Treatment of aggressive non-Hodgkins lymphoma with anti-CD20 antibody
US6762032B1 (en) 1999-08-23 2004-07-13 Biocrystal, Ltd. Compositions, assay kits, and methods for use related to a disease condition comprising multiple sclerosis and/or a pro-MS immune response
DE60120356T2 (de) 2000-02-08 2007-06-14 Genentech, Inc., South San Francisco Verbesserte galactosylierung von rekombinanten proteinen
KR20020091170A (ko) 2000-03-31 2002-12-05 아이덱 파마슈티칼즈 코포레이션 Ｂ 세포 림프종의 치료를 위한 항-사이토카인 항체 또는길항제 및 항-ｃｄ２０의 조합된 사용
EP1286692A4 (en) 2000-04-25 2004-11-17 Idec Pharma Corp INTRATHECAL ADMINISTRATION OF RITUXIMAB FOR THE TREATMENT OF LYMPHOMAS OF THE CENTRAL NERVOUS SYSTEM
EP1299128A2 (en) 2000-06-20 2003-04-09 Idec Pharmaceuticals Corporation Cold anti-cd20 antibody/radiolabeled anti-cd22 antibody combination
US6300525B1 (en) 2000-09-01 2001-10-09 Milliken & Company Method of producing fluorinated and chlorinated benzaldehydes and compositions thereof
US20020128448A1 (en) 2000-10-20 2002-09-12 Idec Pharmaceuticals Corporation Variant IgG3 Rituxan and therapeutic use thereof
WO2002062946A2 (en) * 2000-12-08 2002-08-15 Duke University Identification of novel ms4a gene family members expressed by hematopoietic cells
CA2430249A1 (en) 2000-12-14 2002-06-20 Genentech, Inc. Bacterial host strains
US7829084B2 (en) 2001-01-17 2010-11-09 Trubion Pharmaceuticals, Inc. Binding constructs and methods for use thereof
AU2002251913A1 (en) 2001-02-02 2002-08-19 Millennium Pharmaceuticals, Inc. Hybrid antibodies and uses thereof
EP1383532B1 (en) 2001-04-02 2011-05-04 Genentech, Inc. Combination therapy
JP2005500018A (ja) 2001-04-02 2005-01-06 アイデック ファーマスーティカルズ コーポレイション ＧｎＴＩＩＩと同時発現する組換え抗体
WO2003061694A1 (en) 2001-05-10 2003-07-31 Seattle Genetics, Inc. Immunosuppression of the humoral immune response by anti-cd20 antibodies
US7321026B2 (en) * 2001-06-27 2008-01-22 Skytech Technology Limited Framework-patched immunoglobulins
PL374495A1 (en) 2001-10-15 2005-10-31 Immunomedics, Inc. Direct targeting binding proteins
US20030157108A1 (en) 2001-10-25 2003-08-21 Genentech, Inc. Glycoprotein compositions
US20040093621A1 (en) 2001-12-25 2004-05-13 Kyowa Hakko Kogyo Co., Ltd Antibody composition which specifically binds to CD20
US6893885B2 (en) * 2002-01-18 2005-05-17 The Regents Of The University Of Michigan Method for electrically and mechanically connecting microstructures using solder
ATE417858T1 (de) 2002-02-05 2009-01-15 Genentech Inc Proteinaufreinigung
WO2003068801A2 (en) 2002-02-11 2003-08-21 Genentech, Inc. Antibody variants with faster antigen association rates
CA2476166C (en) 2002-02-14 2011-11-15 Immunomedics, Inc. Anti-cd20 antibodies and fusion proteins thereof and methods of use
US20040002587A1 (en) 2002-02-20 2004-01-01 Watkins Jeffry D. Fc region variants
WO2003072736A2 (en) 2002-02-21 2003-09-04 Duke University Reagents and treatment methods for autoimmune diseases
US20040132101A1 (en) 2002-09-27 2004-07-08 Xencor Optimized Fc variants and methods for their generation
PL216630B1 (pl) * 2002-10-17 2014-04-30 Genmab As Izolowane ludzkie przeciwciało monoklonalne wiążące ludzki CD20, związane z tym przeciwciałem transfektoma, komórka gospodarza, transgeniczne zwierzę lub roślina, kompozycja, immunokoniugat, cząsteczka bispecyficzna, wektor ekspresyjny, kompozycja farmaceutyczna, zastosowanie medyczne, zestaw oraz przeciwciało antyidiotypowe i jego zastosowanie
AU2003287345A1 (en) 2002-10-31 2004-06-07 Genentech, Inc. Methods and compositions for increasing antibody production
EP2368578A1 (en) 2003-01-09 2011-09-28 Macrogenics, Inc. Identification and engineering of antibodies with variant Fc regions and methods of using same
EP2062916A3 (en) 2003-04-09 2009-08-19 Genentech, Inc. Therapy of autoimmune disease in a patient with an inadequate response to a TNF-Alpha inhibitor
AR044388A1 (es) 2003-05-20 2005-09-07 Applied Molecular Evolution Moleculas de union a cd20
AU2004256042A1 (en) 2003-06-05 2005-01-20 Genentech, Inc. BlyS antagonists and uses thereof
RU2370775C2 (ru) 2003-07-29 2009-10-20 Дженентек, Инк. Анализ нейтрализующих антител и его применение
US8147832B2 (en) 2003-08-14 2012-04-03 Merck Patent Gmbh CD20-binding polypeptide compositions and methods
KR20060132554A (ko) 2003-08-29 2006-12-21 제넨테크, 인크. 안과 질병의 항-ｃｄ２０ 치료
EP1689435A4 (en) 2003-10-22 2007-10-03 Univ Rochester ANTI-THYMOCYTE ANTISERUM AND ITS USE FOR TRIGGERING B-CELL APOPTOSIS
GB0324888D0 (en) 2003-10-24 2003-11-26 Novartis Ag Organic compounds
ES2672640T3 (es) 2003-11-05 2018-06-15 Roche Glycart Ag Moléculas de unión a antígeno con afinidad de unión a receptores Fc y función efectora incrementadas

Similar Documents

Publication Publication Date Title
JP2013198490A5 (enExample)
JP2014205674A5 (enExample)
RU2017128882A (ru) Антитела к биотину и способы их применения
JP2017052784A5 (enExample)
JP2013538057A5 (enExample)
JP2016533763A5 (ja) ヒトｐｄ−１に特異的に結合する抗体抗原結合ドメインおよびそれを含む医薬組成物
JP2014526898A5 (enExample)
NZ703035A (en) Anti-human respiratory syncytial virus (rsv) antibodies and methods of use
RU2016100892A (ru) Антитела против tweakr и их применение
JP2015028021A5 (enExample)
ES2776179T3 (es) Anticuerpos dirigidos contra determinantes de la superficie de S. aureus
RU2017114341A (ru) Антитела к pd-l1, связывающие pd-l1 собаки
JP2015163068A5 (enExample)
JP2010526028A5 (enExample)
FI3487882T3 (fi) Gprc5d-vasta-aineita, bispesifisiä antigeeniä sitovia molekyylejä, jotka sitovat gprc5d:tä ja cd3:a, sekä niiden käyttötapoja
JP2012116856A5 (enExample)
PE20240218A1 (es) Anticuerpos madurados por afinidad y humanizados para fcrh5
AU2016204274A1 (en) Antibodies that bind to OX40 and their uses
ME02678B (me) Antitijela na ox-40 i postupci njihove primjene
JP2015504421A5 (enExample)
NZ728874A (en) Anti-pd-1 monoclonal antibody and obtaining method therefor
NZ602040A (en) Anti-lrp6 antibodies
JP2015535828A5 (enExample)
RU2017134495A (ru) Антитела к альфа-рецептору собачьего интерлейкина-4
JP2011517447A5 (enExample)